: Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd), often respond to immune checkpoint blockade therapies, while those with mismatch repair-proficient (MMRp) tumors generally do not. Interestingly, a subset of MMRp CRCs contains variable fractions of MMRd cells, but it is unknown how their presence impacts immune surveillance. We asked whether modulation of the MMRd fraction in MMR heterogeneous tumors acts as an endogenous cancer vaccine by promoting immune surveillance. To test this hypothesis, we use isogenic MMRp (Mlh1+/+) and MMRd (Mlh1-/-) mouse CRC cells. MMRp/MMRd cells mixed at different ratios are injected in immunocompetent mice and tumor rejection is observed when at least 50% of cells are MMRd. To enrich the MMRd fraction, MMRp/MMRd tumors are treated with 6-thioguanine, which leads to tumor rejection. These results suggest that genetic and pharmacological modulation of the DNA mismatch repair machinery potentiate the immunogenicity of MMR heterogeneous tumors.

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance

Amodio, Vito;Lamba, Simona;Cattaneo, Chiara M;Corti, Giorgio;Rospo, Giuseppe;Berrino, Enrico;Bartolini, Alice;Marchio', Caterina;Di Nicolantonio, Federica;Germano, Giovanni
;
Bardelli, Alberto
2023-01-01

Abstract

: Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd), often respond to immune checkpoint blockade therapies, while those with mismatch repair-proficient (MMRp) tumors generally do not. Interestingly, a subset of MMRp CRCs contains variable fractions of MMRd cells, but it is unknown how their presence impacts immune surveillance. We asked whether modulation of the MMRd fraction in MMR heterogeneous tumors acts as an endogenous cancer vaccine by promoting immune surveillance. To test this hypothesis, we use isogenic MMRp (Mlh1+/+) and MMRd (Mlh1-/-) mouse CRC cells. MMRp/MMRd cells mixed at different ratios are injected in immunocompetent mice and tumor rejection is observed when at least 50% of cells are MMRd. To enrich the MMRd fraction, MMRp/MMRd tumors are treated with 6-thioguanine, which leads to tumor rejection. These results suggest that genetic and pharmacological modulation of the DNA mismatch repair machinery potentiate the immunogenicity of MMR heterogeneous tumors.
2023
41
1
196
209
6-thioguanine; heterogeneity; immune checkpoint blockade; immune evasion; immune surveillance; microsatellite unstable tumors (MSI); mismatch repair; temozolomide
Amodio, Vito; Lamba, Simona; Chilà, Rosaria; Cattaneo, Chiara M; Mussolin, Benedetta; Corti, Giorgio; Rospo, Giuseppe; Berrino, Enrico; Tripodo, Claudio; Pisati, Federica; Bartolini, Alice; Aquilano, Maria Costanza; Marsoni, Silvia; Mauri, Gianluca; Marchio', Caterina; Abrignani, Sergio; Di Nicolantonio, Federica; Germano, Giovanni; Bardelli, Alberto
File in questo prodotto:
File Dimensione Formato  
2022-Genetic and pharmacological.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 3.3 MB
Formato Adobe PDF
3.3 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1885473
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact